New Launch6 Mar 2025, 08:38 pm
AstraZeneca Pharma India Receives Approval for Sodium Zirconium Cyclosilicate in India
AI Summary
AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import pharmaceutical formulations of new drug Sodium Zirconium Cyclosilicate for sale or distribution in India. The drug, available in 5 g and 10 g oral suspension (Lokelma), is indicated for the treatment of hyperkalaemia in adult patients. This approval marks the way for the launch of the drug in India, subject to the receipt of related statutory approvals.
Key Highlights
- AstraZeneca Pharma India Limited receives approval for Sodium Zirconium Cyclosilicate (Lokelma) in India
- The drug is indicated for the treatment of hyperkalaemia in adult patients
- Available in 5 g and 10 g oral suspension forms
- The approval marks the way for the launch of the drug in India
- Further approvals, if any, are awaited for the official launch